Clik here to view.
Teva and Takeda Establish Unique Partnership to Meet the Wide-Ranging Needs...
JERUSALEM & OSAKA, Japan Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Takeda Pharmaceutical Company Limited (TOKYO:4502) today announced that the two companies have entered into...
View ArticleClik here to view.
Teva and Takeda Establish Unique Partnership to Meet the Wide-Ranging Needs...
JERUSALEM & OSAKA, Japan Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced that the two companies have entered into a...
View ArticleClik here to view.
テバ社と武田薬品による日本における合弁会社設立に関する基本合意契約締結について
イスラエル・エルサレム & 大阪 （ビジネスワイヤ） — Teva Pharmaceutical Industries Ltd.（本社：イスラエル...
View ArticleClik here to view.
Chugai Pharma Marketing Changed Its Corporate Name to Chugai Pharma Europe
TOKYO Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Chugai Pharma Marketing Ltd., a wholly-owned subsidiary of Chugai located in London, changed its corporate name to Chugai...
View ArticleClik here to view.
Sosei Subsidiary Heptares Enters Strategic Drug Discovery Collaboration with...
TOKYO Sosei Group Corporation (“Sosei”) (TOKYO:4565) today announces that its wholly-owned subsidiary, Heptares Therapeutics has entered into a strategic drug discovery collaboration with Pfizer...
View ArticleClik here to view.
Astellas and Ironwood Report Positive Top-Line Data from Phase III IBS-C...
TOKYO & CAMBRIDGE, Mass. Astellas Pharma Inc. (TSE: 4503) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the Phase III clinical trial of linaclotide conducted in Japan in...
View ArticleClik here to view.
Medication Adherence Platform, MedAdvisor, Lists on the ASX
MELBOURNE, Australia MedAdvisor Limited (MedAdvisor or Company) an Australian software developer focused on improving health outcomes by placing patients at the centre of connected health platforms,...
View ArticleClik here to view.
Teva与武田确立独特伙伴关系，以顺应日本患者的多样化需求和仿制药用药不断增长的重要性
耶路撒冷和日本大阪 (美国商业资讯) — Teva Pharmaceutical Industries Ltd. （NYSE和TASE:...
View ArticleClik here to view.
Acelity Acquires SNaP® Disposable Negative Pressure Wound Therapy System to...
SAN ANTONIO Acelity, a global wound care and regenerative medicine company, announced it has acquired the SNaP® Therapy System, a disposable negative pressure wound therapy (NPWT) line of products...
View ArticleClik here to view.
Medidata Partners with Leading Korean CRO C&R Research to Optimize Study...
NEW YORK & SEOUL, South Korea Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, and C&R Research (C&R), a leading South...
View ArticleClik here to view.
Study Shows Flexor® Parallel™ Rapid Release™ Ureteral Access Sheath Allows...
BLOOMINGTON, Ind. A recent study by Breda et al shows that the Flexor® Parallel™ Rapid Release™ Ureteral Access Sheath (UAS) provides physicians an option to use one wire guide for treatment and...
View ArticleClik here to view.
bluebird bio and ViroMed Enter into License Agreement for Novel Antibodies to...
CAMBRIDGE, Mass. & SEOUL, Korea bluebird bio, Inc. (Nasdaq: BLUE) and ViroMed Co., Ltd. today announced that they have entered into an exclusive license agreement to research, develop and...
View ArticleClik here to view.
Nohla Therapeutics Launches with Major US Cancer Research Institute Deal,...
SEATTLE Nohla Therapeutics Inc. (Nohla), a new cellular therapies start-up based in Seattle, Washington, is pleased to announce the signing of an exclusive licensing and collaboration agreement with...
View ArticleClik here to view.
Frontline BioVentures to Form Strategic Partnership with Sinopharm Group Co.,...
SHANGHAI Frontline BioVentures, a premier healthcare venture capital firm based in China, announced today that it has led a Series A round of financing for Sino Health, an invested company of...
View ArticleClik here to view.
Samsung Bioepis’ RENFLEXIS® Infliximab Biosimilar Receives Regulatory...
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced that Korea’s Ministry of Food and Drug Safety (MFDS) has approved RENFLEXIS® – a biosimilar version of Remicade® (infliximab), also known as...
View ArticleClik here to view.
Promega NanoBiT Complementation Assay Named a Top 10 Innovation
Smart Multimedia Gallery ビデオタイトル QuickTimeで再生 WindowsMediaで再生 MADISON, Wis. The Scientist named Promega NanoBiT™ (NanoLuc® Binary Technology) Assay as a Top 10 Innovation for 2015. This is the third...
View ArticleClik here to view.
武田报告ADCETRIS® (Brentuximab Vedotin)的5年总生存数据，结果显示复发/难治霍奇金淋巴瘤可持久缓解
佛罗里达州奥兰多 (美国商业资讯) — 武田药品工业株式会社(TSE:4502)发布了 brentuximab vedotin单药治疗自体干细胞移植(ASCT)后复发或难治霍奇金淋巴瘤枢纽性2期研究的治疗后随访数据。数据显示，ADCETRIS治疗患者的5年总生存(OS)率估值为41% (95% CI: 31%, 51%)；中位OS期为40.5个月（95% CI: 28.7, 61.9...
View ArticleClik here to view.
Takeda and Cour Partner to Develop Novel Therapies for Celiac Disease and...
OSAKA, Japan & CHICAGO Takeda Pharmaceutical Company Limited (TOKYO:4502) and Cour Pharmaceutical Development Company, Inc. today announced a partnership to research and develop novel immune...
View ArticleClik here to view.
武田薬品とCour社のセリアック病等の消化器疾患に対する治療薬の共同研究開発契約について
大阪 & シカゴ （ビジネスワイヤ） — 武田薬品（本社：大阪市中央区、以下「武田薬品」）とCour Pharmaceuticals Development Company,...
View ArticleClik here to view.
武田が多発性骨髄腫の治療のために最近承認された週1回経口プロテアソーム阻害薬として初にして唯一のNINLARO®（イキサゾミブ）の第3相TOURMALIN...
米フロリダ州オーランド （ビジネスワイヤ） —...
View Article